Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery (CO-ADD) discusses his work towards uncovering compounds with antibiotic potential and shares his thoughts on the best strategies to tackle antibiotic resistance moving forwards.
Browsing: Basic > Drug Development
Researchers from Durham University have developed a new, simplified production process for a drug vital to treating cryptococcal meningitis; they hope this will reduce the drug’s cost and increase its availability in developing countries.
Researchers have discovered a novel regulator of the innate immune response that may lead to the development of new antivirals and vaccines.
Researchers have uncovered the role of inflammasome activation in leishmaniasis progression and severity, demonstrating that inhibiting these pathways may present a potential avenue for future treatments.
The WHO has published a report this week listing 12 families of antibiotic-resistant bacteria that are thought to pose the greatest public health risk and should be the focus for new treatments.
Could nanoconstructs be utilized to fight infection? This Editorial discusses the potential of photoactivatable nanodrugs to overcome the growing problem of acquired antibiotic resistance in bacteria as well as the intrinsic resistance of biofilm-associated infections.
In this study the authors delve into fighting antibiotic resistance, aiming to synthesize and evaluate the antimicrobial activity of a new series of quinazolinone azolyl ethanols .
This perspective discusses the urgent need for novel and efficient antimicrobial strategies against C. difficile and the authors evaluate the application of the acyldepsipeptides family of antibiotics to treat C. difficile infections.
In this review the authors discuss the limitations of current oral combination antiretroviral therapy and advances in anti-HIV nanoformulations.